Figure 3.

KAI eye drop shows efficacy to inhibit laser-induced CNV. (A, B, C) The effect of KAI as an eye drop was tested and compared with the effect of the intravitreal injection of anti-VEGF antibody in the CNV model. After laser photocoagulation, mice were treated with (1) control peptide (5 µg/eye) eye drop daily (days 1∼14), (2) KAI (2 µg/eye) eye drop daily (days 1∼14), (3) KAI (5 µg/eye) eye drop daily (days 1∼14), (4) KAI (5 µg/eye) eye drop daily (days 7∼14), (5) intravitreal injection of IgG 2 µg/eye at day 1, (6) intravitreal injection of anti-VEGF antibody 2 µg/eye at day 1, and (7) anti-VEGF antibody 2 µg/eye at day 7. (Groups 1∼7 were plotted in graphs B and C starting from the left.) Representative images of the laser burn at day 1, OCT, and angiography at days 7 and 14, and staining of the flat-mount of choroid/sclera with ILB4 on day 14 were shown in A and Supplementary Figure S2. Bars: 100 µm for OCT, 200 µm for ILB4 staining. Four laser burns were induced in each mouse, and the average neovascularization area per mouse was shown in graphs B and C. The cross-section of the CNV area in OCT at day 14 was measured and plotted in graph B. One-way ANOVA (N = 15, 15, 11, 4, 8, 8, and 4 in each group, respectively). Mice with mild cataract because of anesthesia were unable to be monitored by OCT and were omitted from the measurement. CNV surface area of the flat-mount was assessed by the area of ILB4-staining and plotted in graph C. One-way ANOVA (N = 15, 14, 13, 4, 7, 8, and 3 in each group, respectively). Three choroidal tissues were damaged during the preparation of flat mount, and we were unable to assess the area of CNV. One-way ANOVA.